Positive News SentimentPositive NewsNASDAQ:SLS SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis $1.11 -0.05 (-4.31%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.12 +0.01 (+1.35%) As of 03/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About SELLAS Life Sciences Group Stock (NASDAQ:SLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SLS alerts:Sign Up Key Stats Today's Range$1.11▼$1.1650-Day Range$0.99▼$1.6252-Week Range$0.77▼$1.84Volume750,644 shsAverage Volume1.39 million shsMarket Capitalization$78.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Read More… Remove Ads SELLAS Life Sciences Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreSLS MarketRank™: SELLAS Life Sciences Group scored higher than 8% of companies evaluated by MarketBeat, and ranked 933rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for SELLAS Life Sciences Group. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SELLAS Life Sciences Group are expected to grow in the coming year, from ($0.57) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SELLAS Life Sciences Group is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SELLAS Life Sciences Group is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about SELLAS Life Sciences Group's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.29% of the float of SELLAS Life Sciences Group has been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently increased by 0.51%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSELLAS Life Sciences Group does not currently pay a dividend.Dividend GrowthSELLAS Life Sciences Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.29% of the float of SELLAS Life Sciences Group has been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently increased by 0.51%, indicating that investor sentiment is decreasing. News and Social Media2.7 / 5News SentimentN/A News SentimentSELLAS Life Sciences Group has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for SELLAS Life Sciences Group this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for SLS on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SELLAS Life Sciences Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of SELLAS Life Sciences Group is held by insiders.Percentage Held by InstitutionsOnly 17.38% of the stock of SELLAS Life Sciences Group is held by institutions.Read more about SELLAS Life Sciences Group's insider trading history. Receive SLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter. Email Address SLS Stock News HeadlinesSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 21, 2025 | finanznachrichten.deSELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 20, 2025 | globenewswire.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…March 30, 2025 | Paradigm Press (Ad)Sellas reports Phase IIa trial data of SLS009 for DLBCL treatmentFebruary 21, 2025 | msn.comSELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLFebruary 20, 2025 | finanznachrichten.deSELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trialFebruary 20, 2025 | msn.comSellas Life Sciences’ zanubrutinib combination shows efficacy in DLBCLFebruary 20, 2025 | markets.businessinsider.comSELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLFebruary 20, 2025 | globenewswire.comSee More Headlines SLS Stock Analysis - Frequently Asked Questions How have SLS shares performed this year? SELLAS Life Sciences Group's stock was trading at $1.04 on January 1st, 2025. Since then, SLS stock has increased by 6.7% and is now trading at $1.11. View the best growth stocks for 2025 here. How were SELLAS Life Sciences Group's earnings last quarter? SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced its quarterly earnings data on Thursday, March, 20th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. When did SELLAS Life Sciences Group's stock split? SELLAS Life Sciences Group shares reverse split before market open on Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are SELLAS Life Sciences Group's major shareholders? SELLAS Life Sciences Group's top institutional shareholders include Anson Funds Management LP (1.69%), Geode Capital Management LLC (1.04%), Brooklyn FI LLC (0.85%) and Brooklyn FI LLC (0.85%). View institutional ownership trends. How do I buy shares of SELLAS Life Sciences Group? Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SELLAS Life Sciences Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that SELLAS Life Sciences Group investors own include (UNISQ) (UNISQ), Amgen (AMGN), Generex Biotechnology (GNBT), Salesforce (CRM), Bank of America (BAC), Bristol-Myers Squibb (BMY) and AbbVie (ABBV). Company Calendar Last Earnings3/20/2025Today3/30/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLS CIK1390478 Webwww.sellaslifesciences.com Phone(646) 200-5278Fax441-400-2875Employees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-629.46% Return on Assets-178.65% Debt Debt-to-Equity RatioN/A Current Ratio2.26 Quick Ratio2.26 Sales & Book Value Annual Sales$1 million Price / Sales78.12 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-4.44Miscellaneous Outstanding Shares70,382,000Free Float69,537,000Market Cap$78.12 million OptionableNot Optionable Beta2.43 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:SLS) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.